Irritable Bowel Syndrome Drugs Market Size

  • Report ID: 3040
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Irritable Bowel Syndrome Drugs Market Size

Irritable Bowel Syndrome Drugs Market size was over USD 4.14 billion in 2024 and is projected to cross USD 11.53 billion by the end of 2037, growing at more than 8.7% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of irritable bowel syndrome drugs is estimated at USD 4.43 billion. The growth of the market can be attributed to the increasing number of elderly people who are prone to different types of gastrointestinal diseases. Further, the growing prevalence of gastrointestinal diseases amongst other population group, an increase in the consumption of unhealthy foods, and rising stress levels among people across the globe are also expected to add to the market growth. The estimated prevalence of irritable bowel syndrome in the United States is between 11% and 14% and this share is predicted to increase further in the years to come.

In addition to these, factors that are believed to fuel the market growth of irritable bowel syndrome drugs include the rise in over-the-counter drug availability, soaring investments, and collaboration between major key players to discover effective treatments for IBS. For instance, on June 9, 2022, the biopharmaceutical company Ferring B.V. announced a strategic partnership with the innovation-focused global biopharma company I-MAB Biopharma Co., Ltd. to advance the development of olamkicept, a selective interleukin-6 (IL-6) trans-signaling inhibitor for inflammatory bowel disease (IBD) and associated inflammatory conditions. Additionally, the growing number of awareness campaigns on the management of irritable bowel syndrome is predicted to present the potential for market expansion over the projected period.


Irritable Bowel Syndrome Drugs Market Overview
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3040
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of irritable bowel syndrome drugs is estimated at USD 4.43 billion.

The irritable bowel syndrome drugs market size was over USD 4.14 billion in 2024 and is projected to cross USD 11.53 billion by the end of 2037, growing at more than 8.7% CAGR during the forecast period i.e., between 2025-2037. Increasing incidences of irritable bowel syndrome and growing availability of over the counter drugs will impel the market growth.

North American region is anticipated to hold the largest share by 2037, driven by increasing frequency of fecal incontinence and the availability of efficient treatment options in the region.

The major players in the market include Abbott Services, Ardelyx, Inc., Astellas Pharma Inc., AstraZeneca, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Novartis AG, Ironwood Pharmaceuticals, Inc., Synergy Pharma Consultancy Private Limited, Synthetic Biologics, Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample